BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Business Wire
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutationPreliminary data suggest promising efficacy and tolerabilitySafety profile was consistent with results of prior BRUKINSA studies SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) with del(17p) and/or TP53 mutation. The preliminary data demonstrate that in the 65 response-evaluable patients treated with the com
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 [Yahoo! Finance]Yahoo! Finance
- BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) RegionBusiness Wire
- BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire
- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL [Yahoo! Finance]Yahoo! Finance
BGNE
Earnings
- 5/8/24 - Beat
BGNE
Sec Filings
- 6/24/24 - Form 144
- 6/24/24 - Form 144
- 6/24/24 - Form 144
- BGNE's page on the SEC website